Montgomery M T, Redding S W, LeMaistre C F
Oral Surg Oral Med Oral Pathol. 1986 Mar;61(3):238-42. doi: 10.1016/0030-4220(86)90368-3.
Oral lesions in twenty-nine immunocompromised patients were evaluated for the incidence of herpes simplex virus (HSV) infections during either cancer chemotherapy or cancer chemotherapy plus bone marrow transplantation (BMT). Patients' HSV antibody titers were not determined, and positive diagnoses were based solely on the results of viral cultures. Fourteen patients (48%) were found to have herpetic infections, which is comparable with incidence rates of 50% to 90% in antibody-positive patients and 40% to 50% in mixed antibody populations reported in the medical literature. However, this finding is in conflict with the 10.7% to 15.1% incidence rate cited in the dental literature for patients undergoing cancer chemotherapy. This underestimation is believed to reflect insensitivity in the criteria used for diagnosis in these studies.
对29名免疫功能低下患者的口腔病变进行了评估，以确定在癌症化疗或癌症化疗加骨髓移植（BMT）期间单纯疱疹病毒（HSV）感染的发生率。未测定患者的HSV抗体滴度，阳性诊断仅基于病毒培养结果。发现14名患者（48%）有疱疹感染，这与医学文献中报道的抗体阳性患者50%至90%以及混合抗体人群40%至50%的发生率相当。然而，这一发现与牙科文献中引用的接受癌症化疗患者10.7%至15.1%的发生率相冲突。据信，这种低估反映了这些研究中使用的诊断标准不够敏感。
